Matthew Jarud Shaffer

Title: Matthew Jarud Shaffer: Innovator in Pharmaceutical Compositions

Introduction

Matthew Jarud Shaffer is a notable inventor based in Bend, OR (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions that enhance drug delivery and efficacy. With a total of 2 patents, his work focuses on addressing critical health issues through innovative solutions.

Latest Patents

Shaffer's latest patents include groundbreaking inventions. One of his patents is titled "Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto." This invention pertains to high drug load compositions of medium chain triglycerides (MCT) and methods for treatment that effectively elevate ketone body concentrations. This is particularly relevant for treating conditions associated with reduced neuronal metabolism, such as Alzheimer's disease. Another significant patent is "Pharmaceutical compositions and dosage forms," which relates to compositions comprising N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)-benzamide and a polymer. This patent also includes dosage forms and methods for treating subjects with cancer.

Career Highlights

Throughout his career, Matthew has worked with several prominent companies in the pharmaceutical industry. Notable among these are Ignyta, Inc. and Cerecin Inc. His experience in these organizations has contributed to his expertise in developing innovative pharmaceutical solutions.

Collaborations

Matthew has collaborated with several professionals in his field, including Robert L. Orr and Kathryn Emily Colombo Pugh. These collaborations have likely enriched his work and contributed to the success of his inventions.

Conclusion

Matthew Jarud Shaffer is a distinguished inventor whose work in pharmaceutical compositions has the potential to significantly impact healthcare. His innovative patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.